With AJ Bell and Embark confirming they are following Transact down the IPO trail and Nucleus reported to being thinking similarly, Tom Ellis looks at what lies behind the sudden bout of floatation fever sweeping the platform market.
Since Axa sold Elevate to Standard Life in May 2016 and Legal & General parted with Cofunds for a hefty fee in August 2016, little merger and acquisition (M&A) business has taken place in the adviser platform...
Targeting 4% yield
New CEO looking to restructure divisions
Inflows up from £178m for same period last year
European Commission relents to pressure
Latest news and analysis